Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

Low dose valproic acid treatment caused hair loss in a young patient.

A Western diet may increase acne risk, while a Mediterranean diet and certain supplements can help reduce it.

This article reviews human placenta hydrolysates and their complex molecular mechanisms in treating various conditions but does not present new clinical findings.

In this study, sodium valproate as monotherapy stopped seizures in 50% of epileptic children and was most effective in primary generalized and photosensitive epilepsies with notable side effects.

This study found that VPS13C variants are significantly enriched in patients with idiopathic REM sleep behavior disorder (iRBD), associating these variants with more severe symptoms, autonomic dysfunction, and faster progression from iRBD to overt α-synucleinopathy in the iRBD-first disease subtype.

This study introduces a new Drug Efficacy Index to predict the effectiveness of various Ayurvedic hair care formulations and modern medicines.

This review discusses the mechanisms associated with protoporphyrin IX in living cells and reports no clinical results; the authors emphasize its potential in cancer diagnosis and the risks of toxicity.

This study found that valproic acid promoted hair re-growth in C3H mice by activating the Wnt/β-catenin pathway, suggesting its potential as a treatment for alopecia.

In this study, valproic acid treatment was associated with reduced biotinidase activity and improved skin lesions after biotin supplementation in children with seizures.

This study found that in vivo, a novel microneedle system for valproic acid delivery may improve hair regrowth efficacy by upregulating hair follicle development pathways more effectively than topical application.

This study identifies specific molecular components involved in the intracellular trafficking of LGR5, revealing mechanisms that differ from typical GPCR recycling processes.

This review discusses the side effects of carbamazepine, valproate, and clonazepam, noting that these are rare with long-term use but more common, transient, and generally mild during early treatment.

This study found that valproic acid promoted human hair growth by increasing β-catenin levels, suggesting it may be a potential therapeutic option for alopecia.

This review discusses the effects of valproic acid on immune cell activation and gene expression, potentially influencing infection outcomes and suggesting its promise for autoimmune and hypersensitivity condition management.

This study suggests that the interaction between CXXC5 and Dishevelled is a potential target for promoting hair regrowth and hair follicle formation, offering a new approach to treat hair loss.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

This study found that pediatric patients on valproic acid may experience hair loss due to reduced zinc and biotinidase levels within the first 3 months, with zinc depletion continuing to contribute by the 6th month.

This review discusses the interplay between epilepsy and reproductive endocrine disorders, examining the factors involved and emphasizing the importance of monitoring but reports no new research findings.

This study found that selected polymeric pretreatments on hair can significantly reduce breakage and protect against thermal damage from hot flat irons by maintaining cuticle integrity and moisture.

This study found that venous blood ammonia levels, particularly in patients taking valproate combined with other antiepileptic drugs, were significantly elevated compared to those on valproate alone.

This study found that using valproic acid during radiotherapy for glioma was associated with delayed hair loss and improved survival outcomes.

In this study on rats, valproic acid was associated with reduced biotinidase enzyme activity and higher alopecia rates, but biotin supplementation did not significantly affect alopecia occurrence.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

Two studies in Cell Stem Cell reported that human and mouse somatic cells can be reprogrammed into induced pluripotent stem cells using microRNAs, eliminating the need for ectopic protein expression.

Valproic acid can cause hair loss, but information on hair color change is not detailed.

This review, drawing on literature and personal experience, suggests that sodium valproate is a safe and effective antiepileptic drug for various epileptic conditions in children and adults, including the elderly.

This study found that human dermal papilla cells reprogram into induced pluripotent stem cells with higher efficiency than dermal fibroblasts, demonstrating their potential as an alternative source for iPS cells.

This study found that diffuse alopecia in HIV-1-infected patients is characterized by higher rates of follicular stem cell apoptosis compared to controls, suggesting a hair cycle disturbance associated with the infection.

The authors concluded that administering biotin may help prevent alopecia caused by reduced biotinidase activity during valproic acid therapy in rats.